| 7632- | Ins, | The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor |
| - | Review, | Var, | NA |
| 7633- | Ins, | Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use |
| - | Trial, | Nor, | NA |
| 7673- | iod, | Chemo, | Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study |
| - | Trial, | BC, | NA |
| 7672- | iod, | Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study |
| - | Trial, | BC, | NA |
| 7671- | iod, | Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line |
| - | in-vitro, | BC, | MCF7 |
| 7674- | iod, | Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway |
| - | in-vitro, | BC, | NA |
| 7676- | iod, | Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR) |
| - | in-vivo, | BC, | NA |
| 7677- | iod, | Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone |
| - | in-vitro, | BC, | MCF7 |
| 7678- | iod, | Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects |
| - | in-vitro, | Nor, | MCF12A | - | in-vitro, | BC, | MCF7 |
| - | in-vivo, | BC, | MCF7 |
| 7680- | iod, | doxoR, | Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection |
| - | vitro+vivo, | BC, | NA |
| 7681- | iod, | metroC, | Molecular Iodine Improves the Efficacy and Reduces the Side Effects of Metronomic Cyclophosphamide Treatment against Mammary Cancer Progression |
| - | in-vivo, | BC, | NA |
| 7682- | iod, | Molecular Iodine Induces Anti- and Pro-Neoplastic Effects in Prostate Cancer Models |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 7683- | iod, | Se, | Prediagnostic serum iodine and selenium in relation to breast cancer survival |
| - | Study, | BC, | NA |
| 7684- | iod, | Molecular iodine impairs chemotherapy resistance and adverse effects in breast cancer treatments |
| - | Trial, | BC, | NA |
| 7685- | iod, | Could iodine be the missing micronutrient in breast cancer development? |
| - | Review, | BC, | NA |
| 7686- | iod, | Molecular Iodine Exhibited Differential Antiproliferative Actions in Progenitor and Stem Populations from Chemoresistant Cancer Cells |
| - | vitro+vivo, | BC, | MCF7 |
| 7687- | iod, | ESWT, | Shock Wave Application Increases the Antineoplastic Effect of Molecular Iodine Supplement in Breast Cancer Xenografts |
| - | in-vivo, | BC, | MDA-MB-231 |
| 7688- | iod, | CEL, | Iodine prevents the increase of testosterone-induced oxidative stress in a model of rat prostatic hyperplasia |
| - | in-vivo, | Pca, | NA |
| 7689- | iod, | Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines |
| - | in-vitro, | Nor, | RWPE-1 | - | in-vitro, | Pca, | LNCaP | - | vitro+vivo, | Pca, | DU145 |
| 2172- | iod, | A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey |
| - | Study, | Pca, | NA |
| 7652- | IP, | Inulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation |
| - | in-vivo, | Melanoma, | B16-F10 |
| 7654- | IP, | Dietary Supplementation of Inulin Contributes to the Prevention of Estrogen Receptor-Negative Mammary Cancer by Alteration of Gut Microbial Communities and Epigenetic Regulations |
| - | in-vivo, | BC, | NA |
| 7669- | IP, | Colorectal cancer and inulin supplementation: the good, the bad, and the unhelpful |
| - | Review, | CRC, | NA |
| 7653- | IP, | Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel |
| - | in-vivo, | Var, | NA |
| - | in-vivo, | BC, | NA |
| 7656- | IP, | Inulin Modulates Gut Microbiota and Increases Short-Chain Fatty Acids Levels to Inhibit Colon Tumorigenesis in Rat Models: A Systematic Review and Meta-Analysis |
| - | Review, | CRC, | NA |
| 7657- | IP, | Dietary inulin suppresses azoxymethane-induced aberrant crypt foci and colon tumors at the promotion stage in young Fisher 344 rats |
| - | in-vivo, | Var, | NA |
| 7658- | IP, | Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition |
| - | in-vivo, | CRC, | NA |
| 7659- | IP, | Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data |
| - | in-vivo, | Colon, | NA |
| 7660- | IP, | Overview of experimental data on reduction of colorectal cancer risk by inulin-type fructans |
| - | Review, | CRC, | NA |
| - | Trial, | Nor, | NA |
| 7662- | IP, | Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, cross-over, dose-ranging, randomized study in healthy volunteers |
| - | Trial, | Nor, | NA |
| 7663- | IP, | Industrial additive and dietary fiber inulin induces tumor-selective necrotic death via mitochondrial lipid peroxidation involving MYC and YAP |
| 7664- | IP, | GCL2505, | Administration of bifidobacteria and dietary fiber improves cognitive function by increasing short-chain fatty acid-producing bacteria and reducing inflammation |
| - | Trial, | AD, | NA |
| 7665- | IP, | A Prebiotic-Supplemented Formula Improves Gut Microbiota and Intestinal Inflammatory Microenvironment in Patients with Colorectal Adenoma: A Double-Blind, Placebo-Controlled Trial |
| - | Trial, | Nor, | NA |
| 7666- | IP, | Short-chain fatty acid kinetics and concentrations are higher after inulin supplementation in young and older adults: a randomized trial |
| - | Trial, | Nor, | NA |
| 7667- | IP, | H2, | Molecular hydrogen as a potential mediator of the antitumor effect of inulin consumption |
| 7668- | IP, | A phase 2 randomized, placebo-controlled trial of inulin for the prevention of gut pathogen colonization and infection among patients admitted to the intensive care unit for sepsis |
| - | Trial, | Sepsis, | NA |
| 7697- | IP6, | Ins, | Combination of Inositol Hexaphosphate and Inositol Inhibits Liver Metastasis of Colorectal Cancer in Mice Through the Wnt/β-Catenin Pathway |
| - | in-vivo, | CRC, | NA |
| 7713- | IP6, | PacT, | Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vitro, | Oral, | HN5 |
| 7714- | IP6, | ACNs, | Enhanced absorption of anthocyanins after oral administration of phytic acid in rats and humans |
| - | in-vivo, | Nor, | NA |
| 7715- | IP6, | Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma |
| - | in-vitro, | Melanoma, | HTB68 |
| 7716- | IP6, | Inositol hexaphosphate (IP6): a novel treatment for pancreatic cancer |
| - | in-vitro, | Pca, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| - | in-vivo, | Pca, | DU145 |
| 7712- | IP6, | Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice |
| - | in-vivo, | Pca, | NA |
| 7718- | IP6, | Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes |
| - | in-vitro, | Pca, | DU145 |
| 7719- | IP6, | Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells |
| - | in-vitro, | CML, | NA |
| 7720- | IP6, | Protective effect of phytic acid on oxidative DNA damage with reference to cancer chemoprevention |
| - | Review, | Nor, | NA |
| 7721- | IP6, | Ins, | Effect of phytic acid and inositol on the proliferation and apoptosis of cells derived from colorectal carcinoma |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid